Hold Breath: Autonomic Neural Regulation of Innate Immunity to Defend Against SARS-CoV-2 Infection

Changle Wang1†, Yan Zhao1†, Hongxiu Qiao1, Zhiyun Gao1, Jing Yang2 and Xia Chuai1*†

1 Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang, China, 2 International Cooperation Laboratory of Stem Cell Research, Hebei Medical University, Shijiazhuang, China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel member of the genus of betacoronavirus, which caused a pandemic of coronavirus disease 2019 (COVID-19) worldwide. The innate immune system plays a critical role in eliminating the virus, which induces inflammatory cytokine and chemokine secretion, produces different interferons, and activates the adaptive immune system. Interactions between the autonomic nervous system and innate immunity release neurotransmitters or neuropeptides to balance the excess secretion of inflammatory cytokines, control the inflammation, and restore the host homeostasis. However, more neuro-immune mechanisms to defend against viral infection should be elucidated. Here, we mainly review and provide our understanding and viewpoint on the interaction between respiratory viral proteins and host cell receptors, innate immune responses to respiratory viral infection, and the autonomic neural regulation of the innate immune system to control respiratory viruses caused by lungs and airways inflammation.

Keywords: SARS-CoV-2, innate immunity, autonomic neural regulation, respiratory virus, respiratory inflammation

INTRODUCTION

At the end of 2019, an emerging severe acute respiratory infectious disease outbreak occurred in Wuhan, China (Hu et al., 2020). The causative agent that belonged to the genus Betacoronavirus of Coronaviridae family via complete genome sequence was identified and termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organization. SARS-CoV-2 is an enveloped positive-sense single-stranded RNA (+ ssRNA) virus, which consists of nucleocapsid protein (N), membrane protein (M), envelope protein (E), spike protein (S), four structure proteins, 16 non-structural proteins (NSP1-NSP16), and nine putative accessory factors (Suryawanshi et al., 2021). The phylogenetic analysis reveals that, among all human infection-related beta coronaviruses, SARS-CoV-2 is in the same cluster with SARS-CoV that belongs to the subgenus Sarbecovirus. This virus is distant from Middle East respiratory syndrome coronavirus...
autoimmune diseases, bacterial and parasitic infections, via inhibit and control the inflammatory responses of several. Previous studies elucidate that all these ANS division systems work together to balance immune dysregulation and eliminate cytokines, chemokines, and other immune mediators and ANS could be rapidly activated by the secreted inflammatory systemic, regional, and local pathways. The divisions of the pivotal role in regulating the innate immune responses through cell body is located inside the tissue. The ANS plays a nervous system (SNS), the parasympathetic nervous system has three nervous divisions, which include the sympathetic nervous system (SNS), the parasympathetic nervous system (PNS), and the enteric nervous system (ENS). The SNS and even autonomic dysfunction, which were due to the PNS are composed of the nerve fibers projecting from (PNS), and the enteric nervous system (ENS). The SNS and (ENS). The SNS, MERS-CoV and SARS-CoV have been reported that infected human upper or lower respiratory tracts, which caused common cold and fatal pneumonia (Osvyannikova et al., 2020). There are mild, critical, and severe types of clinical manifestations of COVID-19, and most of the confirmed patients showed the mild type (Wiersinga et al., 2020). The symptoms in the majority of the COVID-19 cases include fever, dry cough, fatigue, shortness of breath, and general malaise (Huang et al., 2020; Wiersinga et al., 2020). Furthermore, COVID-19–associated neurological diseases are also reported in clinical COVID-19 cases, such as encephalopathy, encephalitis, psychosis, and neurocognitive syndrome (Ellul et al., 2020). Many hospitalized patients exhibit headache, dizziness, loss of smell and taste, intracerebral hemorrhages, ischemic strokes, and even autonomic dysfunction, which were due to the direct effects of SARS-CoV-2 infection, para- or post-infectious immune-mediated neurological complications (Ellul et al., 2020; Iadecola et al., 2020).

The innate immune system is the first defense line protecting humans from being infected by microbial pathogens. It monitors pathogenic organism invasion and induces cytokine secretion to cause inflammation (Takeuchi and Akira, 2010). The intensity of inflammatory responses is very important for the host to control the pathogenic invader’s infection because inadequate immune responses lead to host immunodeficiency, and excessive immune responses could damage the tissues or organs and even cause host death. The autonomic nervous system (ANS) has three nervous divisions, which include the sympathetic nervous system (SNS), the parasympathetic nervous system (PNS), and the enteric nervous system (ENS). The SNS and the PNS are composed of the nerve fibers projecting from the central nervous system (CNS) and sacral portion of the spinal cord, and the ENS is intrinsic because the neuron’s cell body is located inside the tissue. The ANS plays a pivotal role in regulating the innate immune responses through systemic, regional, and local pathways. The divisions of the ANS could be rapidly activated by the secreted inflammatory cytokines, chemokines, and other immune mediators and work together to balance immune dysregulation and eliminate pathogens (Rankin and Artis, 2018; Godinho-Silva et al., 2019). Previous studies elucidate that all these ANS division systems inhibit and control the inflammatory responses of several autoimmune diseases, bacterial and parasitic infections, via releasing noradrenaline or acetylcholine neurotransmitters and neuropeptides (Sternberg, 2006; Godinho-Silva et al., 2019). However, the studies and data on researching mechanisms of the interplay between the ANS and the innate immune system in defending against SARS-CoV-2 or other respiratory viral infections are limited. Based on the current research, we discuss and explain autonomic neural regulation of the innate immune responses to SARS-CoV-2 infection through adrenergic or cholinergic pathways and neuropeptides in this study.

RESPIRATORY VIRUS BINDING PROTEINS AND HOST CELL RECEPTORS

The interactions between respiratory virus proteins and host cell receptors are the preconditions of the viruses that infect and proliferate in human respiratory epithelial cells or immune cells. After binding to the receptors, the viruses enter into the cytoplasm of the host cells through fusion or endocytosis. The attachment proteins of SARS-CoV-2 and the selected previous human respiratory viruses include S protein (SARS-CoV-2, SARS-CoV, MERS-CoV, HcoV-NL63, 229E, OC43, HKU1), hemagglutinin (influenza A virus H1N1, H5N1, H7N9, measles virus), hemagglutinin-neuraminidase glycoprotein (parainfluenza virus, mumps virus), G glycoprotein (Hendra and Nipah virus, human metapneumovirus, respiratory syncytial virus), fiber protein (human adenovirus), E1 envelope glycoprotein (rubella virus), and VP1-VP2-VP3 complex protein (human rhinovirus), which could facilitate the respiratory viruses entry (Table 1).

On the other hand, angiotensin-converting enzyme 2 (ACE2) is reported as the binding receptor for SARS-CoV-2, SARS-CoV, and HcoV-NL63. In the case of SARS-CoV-2, the ACE2 receptor could be ligand to the receptor-binding domain (RBD) of the S protein, and the S1 and S2 ectodomain segments are demonstrated to function as a binding receptor and membrane fusion, respectively (Hoffmann et al., 2020; Hu et al., 2020). Dipeptidyl peptidase 4 (DPP4) is the receptor for MERS-CoV, aminopeptidase N for HcoV-229E, and 9-O-acetylated sialic acid for HcoV-OC43 and HKU1 (Fung and Liu, 2019). Influenza A viruses, parainfluenza virus, and mumps virus are demonstrated to utilize sialic acid as a receptor, whereas influenza A viruses bind to α-2,6-linked sialic acids on human epithelial cells and α-2,3-linked sialic acids on avian cells (Aguilar et al., 2016; Harthorn, 2020). The remaining -ssRNA viruses, such as measles virus, Hendra and Nipah virus, human metapneumovirus, and the respiratory syncytial virus, can bind to Ephrin B2 and/or B3, signaling lymphocyte activation molecule, CD46, nectin-4, heparan sulfate, Ca2+-dependent C-type lectin receptor DC-SIGN or L-SIGN, nucleolin, intercellular adhesion molecule 1 (ICAM-1), CX3CR1, and other glycosaminoglycans (Table 1). In the case of human adenovirus, coxsackie and adenovirus receptor CD46, desmoglein-2, glycos GD1a, and polysialic acid are reported as binding receptors of this virus (Johnson et al., 2015; Gillespie et al., 2016; Stasiak and Stehle, 2020). Rubella virus and human rhinovirus can utilize myelin oligodendrocyte glycoprotein
TABLE 1 | Summary of SARS-CoV-2 and selected previous human respiratory viruses.

| Respiratory viruses | Types of nucleic acid | Viral attachment proteins | Binding receptors | Human adult cytokine storm | Diseases | References |
|---------------------|-----------------------|---------------------------|-------------------|---------------------------|----------|------------|
| Severe acute respiratory syndrome coronavirus 2 | +ssRNA | Spike protein | Angiotensin-converting enzyme 2 (ACE2), tyrosine-protein kinase receptor UFO (AXL), neuropilin-1 (NRP1) and NRP2, asialoglycoprotein receptor 1 (ASGR1), kringle containing transmembrane protein 1 (KREMEN1) and CD147 | + | Coronavirus disease 2019 | Fung and Liu, 2019; Cantuti-Castelvetri et al., 2020; Day et al., 2020; Hoffmann et al., 2020; Hu et al., 2020; Wang et al., 2020; Gu et al., 2021; Wang et al., 2021 |
| Severe acute respiratory syndrome coronavirus | | ACE2 | + | Severe acute respiratory syndrome | |
| Middle East respiratory syndrome coronavirus | | Dipeptidyl peptidase 4 | + | Middle East respiratory syndrome | |
| Human coronavirus NL63 | | ACE2 | – | Common cold | |
| Human coronavirus 229E | | Aminopeptidase N | – | Common cold | |
| Human coronavirus OC43 | | 9-O-acetylated sialic acid | – | Common cold | |
| Human coronavirus HKU1 | | Segmented -ssRNA | Hemagglutinin | α-2,6-linked sialic acids (human), α-2,3-linked sialic acids (avian) | + | Influenza | Hartshorn, 2020 |
| Influenza A virus H1N1 | | Hemagglutinin-neuraminidase glycoprotein | Sialic acid | – | Common cold, bronchiolitis, pneumonia | Aguilar et al., 2016 |
| Influenza A virus H5N1 | | Hemagglutinin | Signaling lymphocyte activation molecule, CD46 and nectin-4 | – | Mumps | |
| Influenza A virus H7N9 | | Hemagglutinin | – | Measles | Aguilar et al., 2016 |
| Hendra virus | | G glycoprotein | Ephrin B2 | – | Encephalitis, severe respiratory illness | Aguilar et al., 2016 |
| Nipah virus | | Ephrin B2, B3 | – | Common cold, bronchiolitis | Aguilar et al., 2016; Gillespie et al., 2016 |
| Human metapneumovirus | | Heparan sulfate, Ca2+-dependent C-type lectin receptor DC-SIGN or L-SIGN or other glycosaminoglycans | – | Common cold, bronchiolitis, pneumonia | Johnson et al., 2015; Aguilar et al., 2016 |
| Respiratory syncytial virus | | Nucleolin, intercellular adhesion molecule 1 (ICAM-1), CX3CR1 or heparan sulfate | – | Common cold, bronchiolitis, pneumonia | Johnson et al., 2015; Aguilar et al., 2016 |
| Human adenovirus | dsDNA | Fiber protein | Coxsackie and Adenovirus Receptor, CD46, desmoglein-2, glycans GD1a or polysialic acid | + | Common cold, pharyngitis, pneumonia | Stasiak and Stehle, 2020 |
| Rubella virus | +ssRNA | E1 envelope glycoprotein | Myelin oligodendrocyte glycoprotein | – | Rubella | Cong et al., 2011 |
| Human rhinovirus | +ssRNA | VP1-VP2-VP3 complex protein | ICAM-1 | – | Common cold | Norkin, 1996 |
and ICAM-1 as receptors, respectively (Norkin, 1995; Cong et al., 2011). Remarkably, as we summarize in Table 1, one respiratory virus can bind to different types of receptors, and one host cell receptor can be utilized by several respiratory viruses (Table 1).

In addition, the tyrosine-protein kinase receptor UFO (AXL), asialoglycoprotein receptor 1 (ASGR1), kringle containing transmembrane protein 1 (KREMEN1), and CD147 are revealed to be ACE2-independent candidate receptors promoting SARS-CoV-2 infected human pulmonary, hepatic, and renal cell lines (Wang et al., 2020, 2021; Gu et al., 2021). AXL showed a different binding site from ACE2, which could interact with the S protein's N-terminal domain (NTD), but not the RBD (Wang et al., 2021). ASGR1 and KREMEN1 were found that could interact with the RBD and NTD and the S2, RBD, and NTD, respectively (Gu et al., 2021). CD147-S protein is evidenced as a novel route for SARS-CoV-2 infection because CD147 mediates viral entering host cells by endocytosis (Wang et al., 2020).

SARS-CoV-2 showed extremely stronger infection ability because the type II transmembrane serine protease (TMPRSS2), proprotein convertase furin, and lysosome protease are reported to play a critical role in the cleavage of the S protein and promoting the virus entry (Hoffmann et al., 2020; Hu et al., 2020). After the S protein was cleaved into S1 and S2 by the furin protease, it generates a polybasic Arg-Arg-Ala-Arg carboxyl-terminal sequence on S1 that conforms to a C-end rule motif to bind to neuropilin-1 (NRP1) and NRP2 receptors, which significantly potentiates SARS-CoV-2 infectivity (Cantuti-Castelvetri et al., 2020; Daly et al., 2020). It is interesting that while ACE2, TMPRSS2, and NRP1 express in different types of neural cultures derived from human-induced pluripotent stem cells, SARS-CoV-2 could not efficiently replicate and spread in these cultures, but induced type III IFN and IL-8 secretion (Bauer et al., 2021). Furthermore, a recent study reported that non-muscle myosin heavy chain IIA (MYH9) could co-localize with S protein through interacting with the S2 subunit and S1-NTD by its C-terminal domain (PRA). Whereas endosomal or myosin inhibitors could effectively block SARS-CoV-2 entry of PRA-A549 cells, TMPRSS2 inhibitors could not, which indicates that MYH9 facilitates SARS-CoV-2 endocytosis and bypasses TMPRSS2 pathways (Chen et al., 2021).

**INNATE IMMUNITY INDUCES PROINFLAMMATORY CYTOKINE AND INTERFERON PRODUCTION TO VIRUS INFECTION**

The innate immune system is a rapid, non-specific, and conserved defense strategy for monitoring and defending invaded pathogens and activating acquired immune responses. The respiratory epithelial cells, innate immune cells, and soluble immune mediators are considered the front sentinel to form a barrier to defense against microbial infections. Toll-like receptors (TLRs, such as TLR2, TLR3, TLR7, and TLR8), and retinoic acid-inducible gene (RIG-I)-like receptors (RLRs, such as RIG-I, and melanoma differentiation-associated gene 5, MDA5) are reported to recognize viral ssRNA, double-stranded RNA (dsRNA), or DNA; subsequently recruit downstream adaptor proteins (such as mitochondrial antiviral signaling protein or myeloid differentiation primary response 88, MyD88); and activate interferon regulatory factor 3/7 or nuclear factor-kB (NF-kB) to induce type I/III interferons (IFN-I/III) or proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) secretion (Schildgen et al., 2011; Lee et al., 2020; Ovsyannikova et al., 2020; Vabret et al., 2020). Furthermore, the recruitment of MyD88 also could follow the MYD88-TRAF6 (TNF receptor-associated factor 6)-TAK1 (TGF-β-activated kinase 1)-p38-AP-1 (activator protein 1) pathway to induce IFN-I secretion (Fung and Liu, 2019). TLR and RLR mediated IFN-I production could induce the expression of IFN-stimulated genes by the infected and neighboring cells, which trigger in the host an antiviral state. In the case of the current emerging respiratory virus infection, SARS-CoV-2 infection inducing or antagonizing interferon responses remains elusive. SARS-CoV-2 triggers a particular signature that remarkably antagonized the IFN-I and IFN-III responses (Blanco-Melo et al., 2020), which elucidated association with the viral proteins of NSP1, NSP3, NSP15, ORF6, ORF7a/b, and ORF8 (Suryawanshi et al., 2021). However, SARS-CoV-2 infection has also been reported to induce IFN-I and III responses in COVID-19 patients, neural cultures, and human enteroids (Broggi et al., 2020; Bauer et al., 2021; Gilbert et al., 2021; Zhao et al., 2021).

Generally, the proinflammatory cytokines can guide the innate immune cells to move to the virally infected sites and cause inflammation (Figure 1). Once massively produced, they work as a pathogenic factor to drive detrimental hyperinflammation and damage the host tissues and organs. SARS-CoV-2, SARS-CoV, MERS-CoV, influenza A viruses (H1N1, H5N1, H7N9), and human adenovirus are evidenced to trigger a strong dysregulated immune response and cause an adult inflammatory cytokine storm (Table 1; Hartshorn, 2020; Vabret et al., 2020; Li et al., 2021). SARS-CoV ORF3a and ORF8b proteins and unknown specific ligands of SARS-CoV-2 were elucidated that could stimulate nucleotide-binding oligomerization domain (NOD)-like receptors family pyrin domain-containing 3 (NLRP3) inflammasome activation; produce IL-1β, IL-6, and IL-18; and trigger murine and human macrophage pyroptosis (Lee et al., 2020; Rodrigues et al., 2021). On the other hand, SARS-CoV-2 infection was evidenced that enhanced the secretion of IL-1β, IL-2, IL-18, IL-6, IL-7, granulocyte-colony stimulating factor (GCSF), and TNF-α (Blanco-Melo et al., 2020; Huang et al., 2020).

The cytokine storm was observed in severe cases of COVID-19, and high levels of serum L-6, IL-8, TNF-α were indicated that are associated with worse outcomes and shorter survival (Del Valle et al., 2020). Immune dysregulation is considered to play an important role in causing acute respiratory distress syndrome (ARDS) or respiratory failure in COVID-19 patients with macrophage activation syndrome or very low human leukocyte antigen D related expression.
FIGURE 1 | Schematic illustration of the autonomic nervous system regulates the innate immune response to defense against SARS-CoV-2 infection. SARS-CoV-2 infects target cell of human respiratory system through binding the ACE2, AXL, NFR1, NFR2, ASGR1, KREMEN1 and CD147 receptors, and could be facilitated cell entry via TMPRESS2, furin protease and MYH9. The infected cells are triggered to secrete massive proinflammatory cytokines, which could signal the immune cells to move to the viral infected sites and activate the sympathetic and parasympathetic nervous system to regulate the immune response. The noradrenaline and acetylcholine neurotransmitters and neuropeptides are produced to balance the cytokines secretion and bind to the adrenergic and cholinergic receptors to control the airways and lungs inflammation and regulate the functions of the respiratory system.

(Giamarellos-Bourboulis et al., 2020). The mechanisms of these severe cases may be due to host immune hyperactivity, failure to balance the inflammatory responses, or inability to control the viral replication, and details should be elucidated further.

THE AUTONOMIC NEURAL REGULATION OF INFLAMMATION THAT WAS CAUSED BY IMMUNE CELLS AND SECRETED CYTOKINES

The mechanisms of the interactions between the ANS and the innate immune system are very complex and are considered important immunoregulatory hubs. Neuro-immune communications are bidirectional because the innate immune cells and neurons can express neurotransmitter and cytokine receptors (Blake et al., 2019). Crosstalk between the ANS and the innate immunity through the SNS (adrernergic) and the PNS (cholinergic) play a critical role in regulating innate immune cell activation and proinflammatory cytokine production to control host inflammation. Whereas the SNS is reported to inhibit TLR-induced type I interferon responses, which supported virus replication (Collado-Hidalgo et al., 2006), vagal activity was hypothesized to upregulate Type I interferon response genes (Sloan and Cole, 2021). The SNS contains neuronal and hormonal components that can regulate the innate immune system through releasing noradrenaline and adrenaline from noradrenergic sympathetic nerve fibers and the medulla of adrenal glands, respectively (Sternberg, 2006). The binding of adrenaline to β-adrenergic receptors (β-AR) on intraparenchymal pulmonary mononuclear cells could suppress the levels of IL-1β, TNF-α, and IL-6 through activation of cyclic AMP (cAMP) and inhibition of NF-κB (Le Tulzo et al., 1997).

Furthermore, noradrenaline was immunosuppressive on dendritic cells (DCs), natural killer (NK) cells, macrophages, and monocytes by inhibiting IL-1, IL-6, IL-12, IFN-γ, and TNF proinflammatory cytokine secretion but could promote IL-10 anti-inflammatory cytokine production in vitro. Although noradrenaline is reported to increase the migration of monocytes, macrophages, and NK cells, it inhibits the migration of DCs and expression of chemokines CCL19 and CCL21 through upregulation of IL-10 (Sternberg, 2006). In a recent study, murine group 2 innate lymphoid cells (ILC2s) were demonstrated to express β2-AR, which was associated with reducing ILC2 immune responses and type 2 inflammation once treated with β2-AR agonist in vivo (Moriyama et al., 2018). Treatment of neutrophils with noradrenaline for 4 and 24 h can impair and reduce the neutrophil chemotaxis, activation, and phagocytosis (Godinho-Silva et al., 2019).

The PNS regulates the immune responses through afferent and efferent fibers of the vagus nerve to stimulate the inflammatory reflex (Tracey, 2009). Inflammatory products, such as IL-1, which binds to its receptor expressed on the paraganglia cells of the parasympathetic ganglia, then activate the vagus nerve’s...
The autonomic nervous system (ANS) is involved in regulating innate immune responses to infection. Neuropeptides and neurotransmitters from the ANS can modulate immune cell function through adrenergic and cholinergic pathways, providing a negative feedback mechanism to control inflammation.

**The Autonomic Neural System Defends SARS-CoV-2**

Neuropeptides and neurotransmitters can play a role in the control of viral infections. During an immune response, the ANS can regulate innate immune responses through adrenergic and cholinergic pathways and induce neuropeptide secretion, which can modulate anti-inflammatory responses. The sympathetic nervous system (SNS) can increase influenza morbidity and mortality by promoting proinflammatory mediator secretion and preventing inflammation deterioration. However, more detailed mechanisms of the neurotransmitters and neuropeptides in regulating innate immunity should be elucidated in future studies.

**The Autonomic Neural Regulation of Innate Immunity to Control Virus Infection–Caused Respiratory Inflammation**

The SNS and PNS can regulate the functions of the respiratory system, which includes airway and vascular smooth muscle tone, mucous gland secretion, bronchial flow, and permeability, and inflammatory mediator release. Once barrier tissues of the respiratory system are under assault by microbial pathogens, such as bacterial, fungal, or viral infection, the triggered inflammation of airways and lungs could be regulated and inhibited through dense innervation of autonomic and sensory nerves. Neuro-immune interactions can maintain the integrity of the barrier cells and tissues and protect the respiratory system from being infected through antimicrobial mechanisms and clearance of the invaded pathogens.

Generally, respiratory viruses cause 90–95% of acute respiratory infections. These viruses can injure the human respiratory system and other tissues or organs outside the respiratory system, which causes human COVID-19, SARS, MERS, common cold, influenza, bronchiolitis, measles, mumps, encephalitis, pharyngitis, and rubella (Table 1). In a guinea pig model in vivo, parainfluenza virus infection was found to decrease M2 receptor mRNA expression and trigger M2 receptor of pulmonary smooth muscles and parasympathetic ganglia dysfunction and airway hyperreactivity but could be prevented by treatment with IL-1β and TNF-α antagonist anakinra (Rynko et al., 2014). Of note, the SNS can increase influenza virus–induced proinflammatory cytokine and chemokine secretion and exacerbate the viral pathogenesis, which could be inhibited by treatment with a but not a β-adrenergic antagonist. Chemical sympathectomy by 6-hydroxydopamine (6-OHDA) decreased morbidity and mortality of influenza virus–triggered pneumonia due to decreased inflammatory influx of monocytes, neutrophils, and NK cells (Grebe et al., 2010). In a recent study, severe influenza virus infection could increase the synthesis of NPY and Y1R, and deletion of NPY and Y1R genes could attenuate viral replication and proinflammatory cytokine...
secretion. NPY-Y1R could activate the suppressor of cytokine signaling 3 responsible for diminishing antiviral responses and promoting proinflammatory cytokine production, which enhanced the virus infection (Fujiiwara et al., 2019).

In the case of SARS-CoV-2 infection, severe cases of COVID-19 have been reported that developed ARDS, acute lung injury, and even multiple organ failure, ultimately causing the patients’ death (Hu et al., 2020; Wiersinga et al., 2020). One possibility for causing ARDS was due to SARS-CoV-2 infection-induced endothelial dysfunction and immunothrombosis, in which activated neutrophils and monocytes aggregated with platelets and the coagulation cascade that caused microthrombi formation (Bonaventura et al., 2021). On the other hand, SARS-CoV-2 infection induced severe hyperinflammatory syndrome associated with dysregulated innate immune responses as aforementioned (Figure 1), which may result in severe tissue injury with vascular endothelial dysfunction and worsen pulmonary function micro thrombosis (Bonaventura et al., 2021). Of note, cigarette smoke is demonstrated to increase ACE2 expression (Smith et al., 2020), and it is hypothesized that ACE2 increase is induced by nicotine through α7nAChR (Russo et al., 2020). Interestingly, nicotine could activate the cholinergic anti-inflammatory pathway to attenuate the proinflammatory cytokine and chemokine production, whereas inhalation of nicotine may potentiate SARS-CoV-2 infectivity due to the upregulation of ACE2.

According to our understanding and viewpoint, the autonomic neural regulation of the innate immunity to control SARS-CoV-2 infection-induced inflammation is hypothesized that, after SARS-CoV-2 infects target cells of the human respiratory system, it leads to triggering much of the inflammatory cytokine secretion. The released cytokines bind to the receptors of the neurons to activate the SNS and PNS to secrete noradrenaline or acetylcholine neurotransmitters and neuropeptides, which bind to the receptors of the respiratory target cells to suppress excessive proinflammatory cytokine production and regulate physiological functions of the respiratory system to protect against viral infection (Figure 1). Furthermore, the released cytokines could also signal the immune cells to move to the viral infected sites to participate in innate immune responses (Figure 1). In mild cases of COVID-19, the ANS could inhibit overreaction of the innate immune responses, balance the levels of proinflammatory cytokines to prevent forming cytokine storms, and rapidly control the airway and lung inflammation through adrenergic and cholinergic pathways. Autonomic neural regulation of pro-inflammatory cytokine secretion and leukocyte recruitment via the released neurotransmitters and neuropeptides is also considered that could maintain vascular endothelial function homeostasis and prevent forming respiratory immunothrombosis. Because the neurotransmitters and neuropeptides are secreted moderately, the function of the respiratory system might be effectively regulated. Indeed, the ANS could not oversuppress the innate immune responses because excessive immunosuppression may lead to overwhelming viral infection.

In the critical or severe cases of COVID-19, many of the patients succumb to some basic diseases. The levels of the proinflammatory cytokines in the body may be imbalanced. Once infected with SARS-CoV-2, it may exacerbate the imbalance levels that form cytokine storms. The excessive secreted cytokines could recruit more innate immune cells to the virally infected sites to aggravate the hyperinflammation. Although neurotransmitter and neuropeptide production is considered to be increased, the autonomic neural regulation of the innate immune responses may be out of control. In addition, the secreted neurotransmitters and neuropeptides may continuously stimulate the target respiratory tissues and cells, worsen the functions of the airways and lungs, deteriorate the clinical manifestations and outcomes, and ultimately cause respiratory dysfunction and failure.

In summary, although the relevant research and experimental data that could directly elucidate the mechanisms of neuroimmune communications to defend against SARS-CoV-2 infection are still inadequate, we believe that the ANS can orchestrate to regulate the innate immune responses to eliminate infected SARS-CoV-2, restore and maintain innate immune homeostasis, and protect against hyperinflammation and cytokine storm to cause respiratory disorders.

**CONCLUSION**

This study focused on ANS-mediated innate immune responses to defend against SARS-CoV-2 infection. We discussed the interactions of respiratory virus binding proteins and host cell receptors, the innate immunity induces proinflammatory cytokine and interferon production to antiviral infection, and the ANS regulates the antiviral infection role of the innate immune system to control respiratory inflammation.

SARS-CoV-2 has become a global threat, which caused more than 400 million people to be infected. Unfortunately, effective drugs or therapies of treatment for COVID-19 patients have not been found. Although nicotine is suggested to alleviate immune dysregulation and inhibit cytokine storm, inhalation of nicotine from tobacco could increase the risk of SARS-CoV-2 infection due to upregulation of ACE2. Two population-based clinical cohort studies revealed and analyzed that treatment of influenza, pneumonia, or ARDS patients with α1-adrenergic blockers could reduce 30-day mortality, risk of intensive care unit admission, mechanical ventilation, and death (Koenene et al., 2021; Thomsen et al., 2021). In future studies, research and development of therapeutic strategies or drugs that can inhibit and counterbalance inflammatory cytokine secretion through adrenergic and cholinergic pathways are considered that may play an important role in helping us bring some enlightenment for treating COVID-19. According to our understanding, one possibility of the therapy strategies for treating the severe cases of COVID-19 might be stimulation of β-AR on the innate immune cells via binding noradrenaline neurotransmitters and blockade of α1-adrenergic receptors via its antagonists. The acetylcholine neurotransmitters or neuropeptides also could be employed for hyperinflammation and cytokine storm therapy strategies. Taken together, to better
understand the autonomic neural regulation of SARS-CoV-2 infection triggered innate immune responses can provide a theoretical and experimental basis for clinical diagnosis and treatment of COVID-19.

**AUTHOR CONTRIBUTIONS**

CW, YZ, JY, and XC wrote and edited the manuscript. HQ and ZG searched the references. All authors contributed to the article and approved the submitted manuscript.

**REFERENCES**

Aguiar, H. C., Henderson, B. A., Zamora, J. L., and Johnston, G. P. (2016). Paramyxovirus Glycoproteins and the Membrane Fusion Process. *Curr. Clin. Microbiol. Rep.* 3, 142–154. doi: 10.1007/s40588-016-0040-8

Bauer, L., Lendemeijer, B., Leijten, L., Embregts, C. W. E., van Tassell, B., Lendemeijer, B., Leijten, L., Embregts, C. W. E., Rockx, B., Kushner, S. A., et al. (2021). Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2 and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models. *mSphere* 6:e0027021. doi: 10.1128/mSphere.00270-21

Blake, K. J., Jiang, X. R., and Chiu, I. M. (2019). Neuronal Regulation of Immunity and approved the submitted manuscript.

**FUNDING**

This work was funded by grants from the National Natural Science Foundation of China (no. 81902026), Science and Technology Project of Hebei Education Department (nos. BJ202018 and QN2018150), Project for the Introduction overseas students of Hebei Provincial Department of Human Resources and Social Security (no. C20200344), S&T Program of Hebei (nos. 20277704D, 20372601D, 20277736D), and the Natural Science Foundation of Hebei Province, China (no. H2020206352).

Wang et al. (2020). Autonomic Neural System Defends SARS-CoV-2

Chandrasekharan, B., Nezami, B. G., and Srinivasan, S. (2013). Emerging pathogenic mechanisms in COVID-19. *PLoS Pathog.* 9, e1003043. doi: 10.1371/journal.ppat.1003043

Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* 26, 1636–1643. doi: 10.1038/s41591-020-1051-9

Delgado, M., Munoz-Elias, E. J., Gomariz, R. P., and Ganea, D. (1999). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. *J. Immunol.* 162, 1707–1716.

Deltente, Y., Herbst, N., Galea, B., Magistrelli, G., Bazzin, I., Bonnefoy, J. Y., et al. (1999). Vasoactive intestinal peptide synergizes with TNF-alpha in inducing human dendritic cell maturation. *J. Immunol.* 163, 3071–3075.

Ellul, M. A., Benjamin, L., Singh, B., Lant, S., Michael, B. D., Easton, A., et al. (2020). Neurological associations of COVID-19. *Lancet Neurol.* 19, 767–783. doi: 10.1016/S1474-4422(20)30221-0

Fujisawa, S., Hoshizaki, M., Ichida, Y., Lex, D., Kuroda, E., Ishii, K. J., et al. (2019). Pulmonary phagocyte-derived NPY controls the pathology of severe influenza virus infection. *Nat. Microbiol.* 4, 258–268. doi: 10.1038/s41564-018-0289-1

Fung, T. S., and Liu, D. X. (2019). Human Coronavirus: host-Pathogen Interaction. *Annu. Rev. Microbiol.* 73, 529–557. doi: 10.1146/annurev-micro-021819-115759

Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., et al. (2020). Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* 26, 992–1000.e3. doi: 10.1016/j.chom.2020.04.009

Gilbert, C., Lefevre, C., Preisser, L., Pivert, A., Soleti, R., Blanchard, S., et al. (2021). Age-Related Expression of IFN-γ Versus IFN-1 and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals. *Front. Immunol.* 12:750279. doi: 10.3389/fimmu.2021.750279

Gillespie, L., Gerstenberg, K., Ana-Sosa-Batiz, F., Parsons, M. S., Farrukke, R., Krabbe, M., et al. (2016). DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans. *J. Virol.* 90, 7848–7863. doi: 10.1128/JVI.00537-16

Godinho-Silva, C., Cardoso, F., and Veiga-Fernandes, H. (2019). Neuro-Immune Cell Units: a New Paradigm in Physiology. *Annu. Rev. Immunol.* 37, 19–46. doi: 10.1146/annurev-immunol-041218-041812

Gomes, R. N., Castro-Faria-Neto, H. C., Bozza, P. T., Soares, M. R., Shoemaker, C. B., David, J. R., et al. (2005). Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. *Shock* 24, 590–594. doi: 10.1097/01.shk.0000183395.29014.7c

Grebe, K. M., Takeda, K., Hickman, H. D., Bailey, A. L., Embry, A. C., Bennink, J. R., et al. (2010). Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. *J. Immunol.* 184, 540–544. doi: 10.4049/jimmunol.0903395

Gu, Y., Cao, J., Zhang, X., Gao, H., Wang, Y., Wang, J., et al. (2021). Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. *Cell Res.* 32, 24–37. doi: 10.1038/s41422-021-00595-6

Hartshorn, K. L. (2020). Innate Immunity and Influenza A Virus Pathogenesis: lessons for COVID-19. *Front. Cell Infect. Microbiol.* 10:563850. doi: 10.3389/fcimb.2020.563850

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 181, 271–280. doi: 10.1016/j.cell.2020.02.052
Hu, B., Guo, H., Zhou, P., and Shi, Z. L. (2020). Characteristics of SARS-CoV-2 and COVID-19. *Nat. Rev. Microbiol.* 19, 141–154. doi: 10.1038/s41579-020-00459-7

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5

Iadecola, C., Anrather, J., and Kamen, H. (2020). Effects of COVID-19 on the Nervous System. *Cell* 183, 16–27.e1. doi: 10.1016/j.cell.2020.08.028

Johnson, S. M., McNally, B. A., Ioannidis, I., Flano, E., Teng, M. N., Oomens, A. G., et al. (2015). Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. *PLoS Pathog.* 11:e1005318. doi: 10.1371/journal.ppat.1005318

Koenecke, A., Powell, M., Xiong, R., Shen, Z., Fischer, N., Huq, S., et al. (2021). Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. *Elife* 10:e61700. doi: 10.7554/elife.61700

Le Tulzo, Y., Shenkar, R., Kaneko, D., Moine, P., Fantuzzi, G., Dinarello, C. A., et al. (2020). Macrophages activate human type I IFN expression in response to SARS-CoV-2. *Nat. Rev. Immunol.* 20, 251–256. doi: 10.1038/s41579-020-00645-2

Suryawanshi, R. K., Koganti, R., Ageidis, A., Patil, C. D., and Shukla, D. (2021). Dysregulation of Cell Signaling by SARS-CoV-2. *Trends Microbiol.* 29, 224–237. doi: 10.1016/j.tim.2020.12.007

Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation. *Cell* 140, 805–820. doi: 10.1016/j.cell.2010.01.022

Thomsen, R. W., Christiansen, C. F., Heide-Jørgensen, U., Vogelstein, J. T., Vogelstein, B., Bettegowda, C., et al. (2021). Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. *JAMA Netw. Open* 4:e2037053. doi: 10.1001/jamanetworkopen.2020.37053

Tracey, K. J. (2009). Reflex control of immunity. *Nat. Rev. Immunol.* 9, 418–428. doi: 10.1038/nri2566

Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., et al. (2020). Immunology of COVID-19: current State of the Science. *Immunity* 52, 910–941. doi: 10.1016/j.immuni.2020.05.002

Vukelic, M., Qing, X., Redecha, P., Koo, G., and Salmon, J. E. (2013). Cholinergic receptors modulate immune complex-induced inflammation in vitro and in vivo. *J. Immunol.* 191, 1800–1807. doi: 10.4049/jimmunol.1203467

Wang, H., Yu, M., Ochani, M., Amella, C. A., Yanovic, M., Susarla, S., et al. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature* 421, 384–388. doi: 10.1038/nature01339

Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J. Q., Du, P., et al. (2020). CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct. Target. Ther.* 5:283. doi: 10.1038/s41392-020-00466-x

Wang, S., Qu, Z., Hou, Y., Deng, X., Xu, W., Zheng, T., et al. (2021). AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Res.* 31, 126–140. doi: 10.1038/s41422-020-00466-x

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., and Prescott, H. C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): a Review. *JAMA* 324, 782–793. doi: 10.1001/jama.2020.12839

Zanetti, S. R., Ziblat, A., Torres, N. I., Zwirner, N. W., and Bouzat, C. (2016). Expression and Functional Role of α7 Nicotinic Receptor in Human Cytokine-stimulated Natural Killer (NK) Cells. *J. Biol. Chem.* 291, 16541–16552. doi: 10.1074/jbc.M115.710574

Zhou, X., Li, C., Liu, X., Chiu, M. C., Wang, D., Wei, Y., et al. (2021). Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus. *Cell Rep.* 16, 493–504. doi: 10.1016/j.celrep.2021.02.009

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Zhao, Qiao, Gao, Yang and Chuai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.